CAR-T immunotherapy, in which a body’s own T cells are reengineered to attack a patient’s tumor, has picked up steam in recent years. But T cells aren’t the only immune cells that scientists are tinkering with.

A team of researchers from the University of Central Florida has found that “natural killer cells” in the body may also play a compelling role in attacking cancer. It may be possible to enhance that response by taking immune cells from a cancer patient’s close blood relatives and infusing those into the patient to attack their tumors. Unlike CAR-T therapy, which so far is restricted to use in blood cancers, there’s hope that these NK cells could be used to treat solid tumors as well.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy